Skeletal events of Anastrozole versus Tamoxifen on bone mineral density and bone biomarker osteocalcin in postmenopausal women with early breast cancer

  • Lobna R. Ezz Elarab
  • Menha Swellam
  • Manal M. Abdel Wahab
  • Karima M. Maher
Article
  • 42 Downloads

Abstract

Objective

Postmenopausal women with breast cancer are at increased risk of bone loss because of age related estrogen deficiency face which accelerated with the use of aromatase inhibitors (AIs). We aimed to study the effect on bone mineral density (BMD) and bone formation biomarker osteocalcin level in postmenopausal breast cancer patients, for the first three years of adjuvant hormonal treatment of both groups Tamoxifen versus Anastrozol.

Methods

One-hundered postmenopausal breast cancers were prospectively randomized to receive either Tamoxifen 20 mg/day (n = 50) or Anastrozole 10 mg (n = 50). Both BMD and osteocalcin were assessed initially before treatment and then at regular intervals for both groups.

Results

Use of Tamoxifen was associated with significant annual decrease in osteocalcin (P = 0.001), whereas Anastrozole group had gradual increase of the annual levels (P < 0.01). BMD decreased significantly in Anastrozole versus Tamoxifen groups (2.6% vs. 0.4%, P < 0.001). Osteoporosis T < −2.5 was reported significantly higher in Anastrozole group (P < 0.01). Women with initial osteopenia in Anastrozole group showed significant decrease in BMD (P < 0.05). The addition of bisphosphonate for patients with early osteoporosis markedly improved both osteocalcin level and BMD.

Conclusion

Tamoxifen preserves BMD in postmenopausal breast cancer patients, whereas Anastrozole accelerates age associated fall in BMD especially in the first year of therapy, moreover, the addition of bisphosphonate can help to decrease the skeletal related events associated with treatment to ensure better quality of life with treatment.

Key words

Anastrozole Tamoxifen, bone mineral density (BMD) breast cancer osteocalcin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Geisler J, Haynes B, Anker G, et al. Influence of letrozole (Femara) and Anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over-designed study. J Clin Oncol, 2002, 20: 751–757.CrossRefPubMedGoogle Scholar
  2. 2.
    Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of Letrozole and Tamoxifen in postmenopausal women with early breast cancer. N Engl J Med, 2005, 353: 2747–2757.CrossRefPubMedGoogle Scholar
  3. 3.
    Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus Tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncol, 2003, 21: 2101–2109.CrossRefPubMedGoogle Scholar
  4. 4.
    Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supple-mentation: a meta-analysis of randomized controlled trials. JAMA, 2005, 293: 2257–2264.CrossRefPubMedGoogle Scholar
  5. 5.
    Seeman E, Delmas PD. Bone quality: the material and structural bases of bone strength and fragility. N Engl J Med, 2006, 354: 2250–2261.CrossRefPubMedGoogle Scholar
  6. 6.
    Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med, 1998, 339: 1609–1618.CrossRefPubMedGoogle Scholar
  7. 7.
    Early Breast Cancer Trialists’ Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet, 1998, 351: 1451–1467.CrossRefGoogle Scholar
  8. 8.
    Cella D, Fallowfield L, Barker P, et al. Quality of life of postmenopausal women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Treat, 2006, 100: 273–284.CrossRefPubMedGoogle Scholar
  9. 9.
    Goss PE, Ingle JN, Martino S, et al. Randomized trial of Letrozole following Tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: update findings from NCIC CTG MA.17. J Natl Cancer Inst, 2005, 97: 1262–1271.CrossRefPubMedGoogle Scholar
  10. 10.
    Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety exemestane versus Tamoxifen after 2–3 years’ Tamoxifen treatment (intergroup Exemestane Study): a randomized controlled trial. Lancet, 2007, 369: 559–570.CrossRefPubMedGoogle Scholar
  11. 11.
    Rogers A, Hannon RA, Eastell R. Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res, 2000, 15: 1398–1404.CrossRefPubMedGoogle Scholar
  12. 12.
    Ma CX, Adjei AA, Salavaggione OE, et al. Human aromatase: gene resequencing and functional genomics. Cancer Res, 2005, 65: 11071–11082.CrossRefPubMedGoogle Scholar
  13. 13.
    Howell A, Cuxick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet, 2005, 365: 60–62.CrossRefPubMedGoogle Scholar
  14. 14.
    Winer EP, Hudis C, Burstein HJ, et al. American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report. J Clin Oncol, 2005, 23: 619–629.CrossRefPubMedGoogle Scholar
  15. 15.
    Lonning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarker, and plasma lipids in patients with surgically resected early breast caner. J Clin Oncol, 2005, 23: 5126–5137.CrossRefPubMedGoogle Scholar
  16. 16.
    Chein AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol, 2006, 24: 5305–5312.CrossRefGoogle Scholar
  17. 17.
    Coleman RE. Effect of Anastrozole on bone mineral density: 5-year results from the Arimidex Tamoxifen Alone or in Combination (ATAC) trial. J Clin Oncol, 2006, 24: 5s.Google Scholar
  18. 18.
    Hillner BE, Ingle JN, Chlebowski RT, et al. American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol, 2003, 21: 4042–4057.CrossRefPubMedGoogle Scholar
  19. 19.
    Johnell O, Kanis J, Oden A. Predictive value of BMD for hip and other fractures. J Bone Min Res, 2005, 7: 1185–1194.CrossRefGoogle Scholar
  20. 20.
    Brufsky AHW, Beck J. Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CITBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole: 12 month BMD results of the Z-FAST trial. J Clin Oncol, 2005, 23: 12s.Google Scholar
  21. 21.
    World Health Organization. Assessment of fracture risk and application to screening for postmenopausal osteoporosis. Geneva, Switzerland, World Health Organization 1994.Google Scholar
  22. 22.
    Baum M, Budzar AU, Cuzick J, et al. ATAC Trialists’ Group: Anasatrozole alone or in combination with Tamoxifen versus Tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer — first results of the ATAC randomized trial. Lancet, 2002, 359: 2131–2139.CrossRefPubMedGoogle Scholar
  23. 23.
    Coombes RC, Hall E, Gibson LJ, et al. Intergroup Exemestane Study: a randomized trial of exemestane after two to three years of Tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med, 2004, 350: 1081–1092.CrossRefPubMedGoogle Scholar
  24. 24.
    Geisler J, King N, Anker G, et al. In vivo inhibition of aromatizaton by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res, 1998, 4: 2089–2093.PubMedGoogle Scholar
  25. 25.
    Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to Tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer, 2001, 92: 2247–2258.CrossRefPubMedGoogle Scholar
  26. 26.
    Goss PE, Ingle JN, Martino S, et al. A randomized trail of letrozole in postmenopausal women after five years of Tamoxifen therapy for early-stage breast cancer. N Engl J Med, 2003, 349: 1793–1802.CrossRefPubMedGoogle Scholar
  27. 27.
    Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to Anastrozole after 2 years’ adjuvant Tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet, 2005, 366: 455–462.CrossRefPubMedGoogle Scholar
  28. 28.
    Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant Tamoxifen: a combination study to NCIC CTG MA.17. J Clin Oncol, 2006, 24: 3629–3635.CrossRefPubMedGoogle Scholar
  29. 29.
    Eastell R, Adams JE, Coleman RE, et al. Effect of Anastrozole on bone mineral density: 5-year results from the Anastrozole, Tamoxifen, alone or in combination trial 18233230. J Clin Oncol, 2008, 26: 1051–1057.CrossRefPubMedGoogle Scholar
  30. 30.
    Eastell R, Hannon RA, Cuzick J, et al. Effect or an aromatase inhibitor on BMD ad bone turnover markers: 2-year results of Anastrozole, Tamoxifen, alone or in combination (ATAC) trial. J Bone Miner Res, 2006, 21: 1215–1223.CrossRefPubMedGoogle Scholar
  31. 31.
    Howell A, Forbes J, Cuzick J, et al. Initial adjuvant therapy with Anastrozole — early and late event data from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial in the hormone-responsive population. St Gallen, 2009 Poster.Google Scholar
  32. 32.
    ATAC Trialists’ Group. Effect of Anastrozole and Tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol, 2008, 9: 45–53.CrossRefGoogle Scholar
  33. 33.
    Brown JP, Josse RG. Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ, 2002, 167: s1–s34.PubMedGoogle Scholar
  34. 34.
    Mincey BA, Duh MS, Thomas SK, et al. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. J Clin Oncol, 2006, 24: 17s.Google Scholar
  35. 35.
    Kanis J, Brogsterom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int, 2005, 16: 581–589.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Lobna R. Ezz Elarab
    • 1
  • Menha Swellam
    • 2
  • Manal M. Abdel Wahab
    • 1
  • Karima M. Maher
    • 3
  1. 1.Radiation Oncology & Nuclear Medicine, Faculty of MedicineAin Shams UniversityCairoEgypt
  2. 2.Biochemistry Department, Genetic Engineering and Biotechnology Research DivisionNational Research CenterDokki, GizaEgypt
  3. 3.Radiology Department, Faculty of MedicineAin Shams UniversityCairoEgypt

Personalised recommendations